NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that class action lawsuits can be filed on behalf of shareholders of Outset Medical, Inc. OmMissfresh Limited MFand StitchFix, Inc. SFIX. Shareholders have until the deadlines below to petition the court to appear as lead plaintiffs. For more information on each case, see the link provided.

Beginning Medical, Inc. Om

Class Period: September 15, 2020 – June 13, 2022

Lead Plaintiff Deadline: September 6, 2022

Outset Medical is a medical technology company focused on renal dialysis, the primary treatment for acute and chronic kidney failure. The Company’s flagship product is the Tablo hemodialysis system (“Tablo”), a dialysis machine that purifies and then artificially purifies tap water and removes toxins from the blood of patients suffering from kidney failure.

The truth began to emerge on May 5, 2022, when the company reported disappointing first-quarter 2022 results that analysts blamed, among other things, on Tablo’s untested nature in the home environment. In response to this disclosure, and as the market digested the news, Outset Medical’s common stock fell more than 40% over the next three trading days from a close of $39.94 per share on Wednesday, March 4. May 9, 2022. to a closing price of $23.06 per share on Monday, May 9, 2022.

Then, after markets closed on June 13, 2022, Outset Medical announced that the FDA had forced the company to hold all supplies of Tablo for home use until Tablo received proper regulatory approval. During an FDA review call held that day with analysts, Defendants acknowledged that the ship hold had been in place for weeks before this material information was provided to investors and that as a result of the Ship Hold “Suspension of our previous full-year guidance and long-term guidance.” In this news, the…